Swayze Eric, EVP of Research at Ionis Pharmaceuticals (IONS), has filed 55 Form 4 transactions, all in a single company, with a pronounced sell-side bias. Over the tracked period, his open-market sales totaled $10.67 million, while he recorded zero open-market purchases. The most recent activity, spanning late 2025 through June 2026, shows 12 open-market sales and no buys, with the largest single disposition occurring on January 2, 2026, when he sold shares worth $1.45 million. Other notable sales include $934,662 on October 1, 2025, $859,082 on October 2, 2025, and $839,492 on June 25, 2026, the most recent transaction in the dataset.
The pattern is consistent with routine executive compensation management rather than a directional bet. His acquisitions, totaling $45,045, came exclusively from option exercises (code M) and stock awards (code A), which are mechanical or compensatory in nature. For instance, on January 2, 2026, he exercised options valued at $1.12 million and simultaneously sold shares worth $1.45 million, a classic exercise-and-sell transaction. Similarly, on October 2, 2025, he exercised options worth $697,504 and sold $859,082 in stock. These paired transactions, along with smaller sales on January 16, 2026 ($744,661) and February 13, 2026 ($769,511 and $509,403), suggest a steady monetization of vested equity.
Notably, there are no open-market purchases (code P) in the entire filing history, which would typically signal conviction in the stock. Instead, the data shows a consistent stream of sales, often tied to option exercises, with no recent accumulation. The absence of buys, combined with the frequency and size of sales, indicates a net reduction in his direct ownership stake over time. While the transactions are not clustered around a single event, the volume and regularity—spanning at least nine months—point to a deliberate, ongoing liquidation of shares, likely for tax or diversification purposes, rather than a reaction to company-specific news.
AI-assisted summary